Reactive oxygen species, antiproteases, and cytokines in sepsis.
Although the shock syndrome is recognized as a form of "mediator poisoning", a plethora of details is hardly converging into a coherent concept of chronological and molecular order. As a model for organ failure in septic shock, three alternative experimental approaches with a common pathology are presented: When galactosamine-sensitized mice receive either lipopolysaccharide or leukotriene D4 or tumor necrosis factor alpha they develop fulminant hepatitis within few hours with a lethal outcome within one day. Detailed pharmacological intervention studies allow to conclude that endotoxin-induced leukotriene D4 release induces a transient ischemia by the known vasoconstrictive action of this eicosanoid. A following reperfusion/reoxygenation phase gives rise to superoxide formation which inactivates alpha 1 proteinase inhibitor. Thus a serine protease becomes active which is responsible for the processing of a monocytic tumor necrosis factor alpha precursor to be released into the circulation after proteolytic cleavage. By this sequence the final central mediator of shock and sepsis becomes systematically abundant. The concept arising from these studies reconciles previously known findings and provides a link between the role of reactive oxygen species in inflammation, the balance of proteases and antiproteases in the extracellular space and the release of the cytokine tumor necrosis factor in sepsis and shock.
Wendel
A
A
Lehrstuhl Biochemische Pharmakologie, Universität Konstanz.
D000818:Animals; D016207:Cytokines / Q000502:physiology*; D010450:Endopeptidases / Q000502:physiology*; D006801:Humans; D007239:Infections / Q000503:physiopathology*; D015289:Leukotrienes / Q000502:physiology; D051379:Mice; D010100:Oxygen / Q000502:physiology*; D012772:Shock, Septic / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D016207:Cytokines; D015289:Leukotrienes; D014409:Tumor Necrosis Factor-alpha; D010450:Endopeptidases; D010100:Oxygen